Tenax Therapeutics, Inc. announced that it will present Phase 3 LEVEL clinical trial results from a Late-Breaking Clinical Science session at the European Society of Cardiology (ESC) Congress 2026. The company expects to report topline data from the Phase 3 LEVEL clinical trial in August 2026. Tenax Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions for cardiovascular diseases.
